PCE Dispertab and Tibsovo

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using ivosidenib together with erythromycin should be avoided if possible. Combining these medications may significantly increase the blood levels of ivosidenib. This may increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). In addition, blood levels of erythromycin may be reduced during treatment with ivosidenib. This may make the medication less effective in treating your condition. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with ivosidenib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivosidenib, which is primarily metabolized by the isoenzyme. Based on physiologically-based pharmacokinetic modeling, coadministration of a 500 mg dose of ivosidenib with the moderate CYP450 3A4 inhibitor fluconazole (dosed to steady-state) is predicted to increase ivosidenib single-dose systemic exposure (AUC) to 173% of control, while multiple-dosing of both is predicted to increase ivosidenib steady-state peak plasma concentration (Cmax) and AUC to 152% and 190% of control, respectively. Increased exposure to ivosidenib may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.

GENERALLY AVOID: Coadministration with ivosidenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4, including many of the known moderate inhibitors of the isoenzyme such as amprenavir, aprepitant, crizotinib, darunavir, diltiazem, dronedarone, erythromycin, imatinib, isavuconazonium, mifepristone, netupitant, and verapamil. Ivosidenib is an inducer of CYP450 3A4 and induces its own metabolism following multiple dosing.

MANAGEMENT: Concomitant use of ivosidenib with moderate CYP450 3A4 inhibitors, particularly those that are also substrates of CYP450 3A4, should generally be avoided. If coadministration is required, close monitoring of electrocardiograms and electrolytes is recommended.

PCE Dispertab

Generic Name: erythromycin

Brand name: EES. Granules, EES-400 Filmtab, EryPed 200, EryPed 400, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab, PCE Dispertab, E. E. S, EryPed, Erythrocin, Erythromycin Filmtabs, Erythromycin Lactobionate - IV

Synonyms: PCE Dispertab (Oral), PCE, PCE (Oral)

What is PCE Dispertab?

Tibsovo

Generic Name: ivosidenib

Brand name: Tibsovo

Synonyms: n.a.

What is Tibsovo?